Erectile dysfunction (ED) is the inability to acquire or sustain a penile erection of sufficient rigidity for sexual intercourse. The condition affects 15 million to 30 million men in the United States. Over time, erections may take longer to develop, be less rigid, or require more direct stimulation. Orgasms may be less intense, the volume of ejaculate frequently decreases, and the refractory period increases.
Related disorders include abnormal curvature of the penis during erection due to fibrosis (Peyronie’s disease), decreased libido, anejaculation or retrograde ejaculation, and premature ejaculation. Any disorder that impairs blood flow to the penis (e.g., atherosclerosis) or causes injury to the penile nerves, smooth muscle, or fibrous tissue has the potential to cause ED.
Changes in erectile function are common. But unexplained ED should not be regarded as benign. ED is often a sign of vascular disease and should be taken as a sign that vascular disease is likely present elsewhere in the body. Patients should be screened for cardiovascular risk factors and treated appropriately in order to prevent myocardial infarction, stroke, or other vascular events.
Some cases are related to endocrine abnormalities, medications (e.g., sympathetic blockers, antidepressants, and antihypertensives), or psychogenic issues. Prostate surgery may lead to ED that may improve over the first 18 months after surgery if nerve-sparing techniques are used. However, irreversible ED is still common after prostate surgery.
Vascular disease. Cardiovascular disease and its risk factors increase the risk of ED. Atherosclerosis causes a reduction in blood flow and accounts for 50%-60% of cases. ED is an early warning sign of future cardiovascular disease. ,
Age. Erectile dysfunction is most common in men older than 65. A bout 5% of 40-year-old men and 15%-25% of 65-year-old men experience some degree of erectile dysfunction. This is not the consequence of age per se, but of accumulated vascular disease, medications, etc.
Diabetes mellitus. At least half of patients with long-standing diabetes experience ED, due to damage of small blood vessels and nerves. Middle aged men with ED should be screened for underlying diabetes as well.
Neurologic conditions. Several neurologic conditions result in ED, including spinal cord and brain injuries, stroke, multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease.
Endocrine disorders. Thyroid disorders, testosterone deficiency (e.g., pituitary tumor and kidney or liver disease), and hyperprolactinemia can result in loss of libido and ED.
Surgery. Colon, prostate, bladder, and rectum surgery may damage erectile nerves and blood vessels. Nerve-sparing techniques decrease impotence incidence to ~ 50%. Cryotherapy of the prostate causes ED in > 90% of men.
Radiation therapy. Radiation treatment for prostate or bladder cancer causes ED in ~ 50% of treated men. The use of brachytherapy may reduce this number.
Medications. More than 200 commonly prescribed drugs are known to cause ED. These include thiazides, antihistamines (e.g., cimetidine), antidepressants (e.g., SSRIs), spironolactone, sympathetic blockers, ketoconazole, and appetite suppressants.
Substance abuse. Excessive use of alcohol, tobacco, marijuana, methylenedioxymethamphetamine (MDMA, better known as Ecstasy), and other recreational drugs can cause ED, which may be irreversible in some cases. For example, excessive tobacco use can permanently damage penile arteries.
Obesity. Excess body fat weight contributes to ED by increasing estrogen activity and aggravating diabetes and lipid disorders.
Psychosocial factors. Stress and depression may contribute to sexual dysfunction, including ED.
A careful medical and sexual history is essential for diagnosis. Sexual history should include onset of symptoms, presence of spontaneous erections (i.e., morning erections), and risk factors. A psychiatric interview and questionnaire may reveal psychological factors, such as depression and anxiety. In some cases, it may be helpful to interview the patient’s sexual partner.
Physical examination can provide clues to systemic problems, such as neurologic abnormalities (e.g., visual field defects that occur with pituitary tumor), vascular abnormalities (e.g., decreased peripheral pulses), developmental abnormalities (e.g., abnormal secondary sex characteristics, penile curvature, gynecomastia), and primary testicular failure (bilaterally small, absent, or undescended testes).
Laboratory evaluation may include serum testosterone, prolactin, and thyroid function tests to evaluate for hormonal abnormalities, particularly if libido is poor. Patients should also be screened for diabetes with fasting glucose or glycated hemoglobin (A1C), kidney and liver function with a comprehensive metabolic profile and cardiovascular risk factors with a lipid profile.
Nocturnal penile tumescence testing can help rule out psychological etiologies, but it is rarely performed because of the ready availability of ED medications. Doppler ultrasound or angiography of the penile arteries may be used to identify arterial occlusion or venous leak, but neither is likely to alter the choice of therapy.
Treatment is aimed at restoring the ability to acquire and sustain erections and reactivating the libido. Diet and lifestyle factors are central to ED treatment and to the prevention of associated cardiovascular conditions, which may be life-threatening.
Smoking cessation and controlling any diabetes and hypertension are also essential.
Stopping and/or changing medications that might be causing ED is important.
The most commonly used class of medications is phosphodiesterase-5 inhibitors (e.g., sildenafil, vardenafil, tadalafil, avanafil). These medications are contraindicated in men taking nitrates and are less likely to be effective in men with diabetes or those who have had prostatectomy.
Hormonal therapy with testosterone may be effective but is only recommended in a small number of patients with documented hypogonadism.
Yohimbine may improve erections and increase libido by stimulating the parasympathetic nervous system, especially in psychogenic ED. (See Nutritional Considerations.)
Treatment of comorbid psychiatric disorders may improve sexual functioning. Between 20%-50% of men with impotence have symptoms of depression, which may contribute to erectile dysfunction. Self-esteem may also suffer as a result of erectile dysfunction. Individual or couples psychotherapy may be a helpful part of impotence treatment.
Vacuum devices, intraurethral therapies (alprostadil), and vasodilating penile injections may be beneficial but are used as second-line treatments when there is no improvement with phosphodiesterase-5 inhibitors
Surgical interventions include implantable prostheses and correction of penile curvature.
Impotence is often the result of vascular disease, and risk factors for cardiovascular disease are commonly found in patients with erectile dysfunction (ED). Risk factors for ED include elevated cholesterol and triglyceride levels, hypertension, obesity, smoking, age, increased waist circumference, indices of low-grade inflammation, ischemic disease, and metabolic syndrome. , , , Moreover, ED should be viewed as a sign that other cardiovascular problems may manifest in the future, and that diet and lifestyle changes to help prevent these problems are essential.
Although the evidence on nutritional treatment is limited, interventions that reduce cardiovascular risk factors or improve blood vessel reactivity (diet, exercise, and certain dietary supplements) may improve symptoms. Weight loss, whether a result of a diet restricted in calories or low in fat, improves ED, as revealed by the International Index of Erectile Function 5-item score (IIEF). Previous research found that a low-fat, low-cholesterol diet combined with exercise resulted in normal sexual function in 31% of men with ED, compared with about 5% in a control group. This combination also significantly reduced several vascular risk factors, including obesity, high blood pressure, elevated serum lipids, and elevated blood glucose and insulin concentrations.
See Coronary Heart Disease chapter for dietary factors to prevent or treat cardiovascular disease.
Dietary supplements are not a substitute for a healthful diet and lifestyle because they do not address the cause of vascular disorders. Nonetheless, dietary supplements, including L-arginine, ginseng, and pycnogenol, have proven effective in treating erectile dysfunction in clinical trials. These appear to work by enhancing nitric oxide release and increasing cyclic guanosine monophosphate (cGMP), which allows penile arterial relaxation and engorgement.
Arginine has appeared in numerous clinical trials to work more effectively in combination with other agents, including adenosine monophosphate, pycnogenol, and yohimbine. In a double-blind, placebo-controlled, two-way crossover, randomized clinical trial in which arginine was given in high doses (8 g/day) in combination with 200 mg of adenosine monophosphate, IIEF scores in the active treatment improved significantly compared with placebo. Pycnogenol, a standardized extract of French maritime pine bark, is a catalyst for endothelial nitric oxide synthase (eNOS). In a double-blind, placebo-controlled clinical trial of 124 men with mild to moderate ED, a daily combination of 80 mg pycnogenol and 2.8 g of arginine resulted in significant improvement in the IIEF score compared with placebo.
Panax ginseng also contains active ingredients (ginsenosides) that increase the release of nitric oxide. Controlled clinical studies have found that mean scores on the IIEF were significantly higher in patients treated with ginseng than in those who received placebo. A meta-analysis concluded that the effects of ginseng on ED are significant but that the methodologic quality of studies makes drawing definitive conclusions difficult. Additional controlled clinical studies are needed to definitively establish a role for ginseng in ED treatment.
Dietary supplements should be used only under medical supervision, due to the possibility of medication interactions. Certain over-the-counter supplements for ED that contain yohimbine, an alpha 2-adrenoreceptor antagonist, have led to at least two deaths.
See chapters on Basic Diet Orders and Coronary Heart Disease.
Referral for psychiatric evaluation, as appropriate.
What to Tell the Family
Discussion with family members regarding the patient’s medical problems should only be done with permission from the patient, particularly in the case of sensitive diagnoses, such as erectile dysfunction. With the patient’s permission, however, the sexual partner may be included in discussions of treatment options.
Patients with impotence are commonly at risk for other cardiovascular problems. Dietary changes, especially a low-fat, vegetarian diet, along with smoking cessation and exercise, can alter these risk factors. To the extent that the entire family adopts such a diet, patient adherence is facilitated, and the patient and family are all likely to benefit.
- Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart. 2003;89(3):251-3. [PMID:12591819]
- Fung MM, Bettencourt R, Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol. 2004;43(8):1405-11. [PMID:15093875]
- Chiurlia E, D'Amico R, Ratti C, et al. Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J Am Coll Cardiol. 2005;46(8):1503-6. [PMID:16226175]
- Brock G. Diagnosing erectile dysfunction could save your patient’s life. Can Urol Assoc J . 2014;8(7-8 Suppl 5):S151-S152.
- Skeldon SC, Detsky AS, Goldenberg SL, Law MR. Erectile dysfunction and the presence of undiagnosed type 2 diabetes, hypertension and hypercholesterolemia. Ann Fam Med . 2015;13:342–346
- Webber R. Erectile dysfunction. Clin Evid . 2003;10:1003-1011.
- Althof SE, Wieder M. Psychotherapy for erectile dysfunction: now more relevant than ever. Endocrine. 2004;23(2-3):131-4. [PMID:15146091]
- Cassidy A, Franz M, Rimm EB. Dietary flavonoid intake and incidence of erectile dysfunction. Am J Clin Nutr. 2016;103(2):534-41. [PMID:26762373]
- Yao F, Huang Y, Zhang Y, et al. Subclinical endothelial dysfunction and low-grade inflammation play roles in the development of erectile dysfunction in young men with low risk of coronary heart disease. Int J Androl. 2012;35(5):653-9. [PMID:22519624]
- Ramírez R, Pedro-Botet J, García M, et al. Erectile dysfunction and cardiovascular risk factors in a Mediterranean diet cohort. Intern Med J. 2016;46(1):52-6. [PMID:26482327]
- Sanjay S, Bharti GS, Manish G, et al. Metabolic syndrome: An independent risk factor for erectile dysfunction. Indian J Endocrinol Metab. 2015;19(2):277-82. [PMID:25729692]
- Khoo J, Ling PS, Tan J, et al. Comparing the effects of meal replacements with reduced-fat diet on weight, sexual and endothelial function, testosterone and quality of life in obese Asian men. Int J Impot Res. 2014;26(2):61-6. [PMID:24196274]
- Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004;291(24):2978-84. [PMID:15213209]
- Neuzillet Y, Hupertan V, Cour F, et al. A randomized, double-blind, crossover, placebo-controlled comparative clinical trial of arginine aspartate plus adenosine monophosphate for the intermittent treatment of male erectile dysfunction. Andrology. 2013;1(2):223-8. [PMID:23413135]
- Ledda A, Belcaro G, Cesarone MR, et al. Investigation of a complex plant extract for mild to moderate erectile dysfunction in a randomized, double-blind, placebo-controlled, parallel-arm study. BJU Int. 2010;106(7):1030-3. [PMID:20184576]
- Choi YD, Park CW, Jang J, et al. Effects of Korean ginseng berry extract on sexual function in men with erectile dysfunction: a multicenter, placebo-controlled, double-blind clinical study. Int J Impot Res. 2013;25(2):45-50. [PMID:23254461]
- Jang DJ, Lee MS, Shin BC, et al. Red ginseng for treating erectile dysfunction: a systematic review. Br J Clin Pharmacol. 2008;66(4):444-50. [PMID:18754850]
- Anderson C, Anderson D, Harre N, et al. Case study: two fatal case reports of acute yohimbine intoxication. J Anal Toxicol. 2013;37(8):611-4. [PMID:23846025]